• Skip to primary navigation
  • Skip to main content
  • Skip to footer

TVM Capital Life Science Venture Capital

Investing in Life Science Innovation

  • About Us
    • Partners
  • Team
  • Senior Advisors
  • Portfolio
  • Funding Request
  • News
  • Events
  • ESG Policy
  • Contact

Cosmo

  • Home
  • About Us
  • Team
  • Senior Advisors
  • Portfolio
  • News
  • Events
  • ESG Policy
  • Contact

News · September 20, 2011

Cosmo announces supportive Top-Line results from Budesonide MMX Extended use study

Submission of NDA in the US for induction of remission of ulcerative colitis planned for December 2011 Lainate (September 20, 2011) – Cosmo Pharmaceuticals SpA, (SIX: COPN), today announced that …

News · July 19, 2011

Cosmo announces the additional approval of LIALDA in the U.S. for the maintenance of remission in patients with ulcerative colitis

LAINATE, ITALY (July 19, 2011) Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced that Shire plc (LSE: SHP, NASDAQ: SHPGY), announced that the U.S. Food and Drug Administration (FDA) approved …

News · June 16, 2011

Cosmo announces live transmission of Blu-Colonoscopy at the International Meeting for Advanced Gastroenterology Endoscopy at Humanitas Hospital in Milano

LAINATE (June 16, 2011) Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced that its Methylene Blue MMX® for the diagnosis of lesions, polyps and adenomas in the colon will be presented in a live …

News · May 31, 2011

Cosmo announces filing of Budesonide MMX® for treatment of mild to moderate active Ulcerative Colitis in Europe

LAINATE (May 31, 2011) Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced that, based on the successfully concluded clinical trials in the US and EU, it had filed the documentation required for …

News · March 25, 2011

Cosmo reports good 2010 operational results

Strategic goals met - Confident outlook for 2011 Lainate, Italy – 25 March 2011 – Cosmo Pharmaceuticals S.p.A. (SIX: COPN) today announced its results for the year ended 31 December 2010. Financial …

  • in

Copyright © 2023 · TVM Capital Life Science Venture Capital · ESG Disclosure · Privacy Policy · Contact